利拉鲁肽对2型糖尿病合并非酒精性脂肪肝患者糖脂代谢及肝脏脂肪沉淀的影响

目的:探讨利拉鲁肽在2型糖尿病合并非酒精性脂肪肝患者中的应用价值。方法:选取2019年8月至2020年8月新乡医学院第一附属医院收治的2型糖尿病合并非酒精性脂肪肝患者150例,按照随机数字表法分为两组,每组各75例。对照组采用常规治疗,观察组采用利拉鲁肽治疗。比较两组血糖、血脂等指标变化、肝脏脂肪沉淀情况及不良反应。结果:治疗前,两组空腹血糖、三酰甘油等指标水平相比,差异无统计学意义(P>0.05);治疗后,观察组空腹血糖、餐后2 h血糖、糖化血红蛋白、三酰甘油、总胆固醇、低密度脂蛋白胆固醇水平分别为(4.37±1.12)mmol/L、(6.57±1.02)mmol/L、(5.01±0.56)%、(1.72±0.59)mmol/L、(5.01±1.06)mmol/L、(2.33±0.54)mmol/L,均低于对照组,差异有统计学意义(P<0.05)。治疗前,两组脂肪受控衰减参数、肝脏硬度指数相比,差异无统计学意义(P>0.05);治疗后,观察组脂肪受控衰减参数、肝脏硬度数值分别为(190.95±38.26)dB/m、(5.46±2.54)kPa,低于对照组,差异有统计学意义(P<0.05)。两组不良反应发生率相当,差异无统计学意义(P>0.05)。结论:利拉鲁肽在2型糖尿病合并非酒精性脂肪肝患者应用价值高,可有效改善其血脂、血糖水平,降低肝脏脂肪沉积,且安全可靠。

Effects of Liraglutide on Glucose and Lipid Metabolism and Liver Fat Deposition in Patients with Type 2 Diabetes Mellitus Complicated with Nonalcoholic Fatty Liver Disease

Objective:To explore the application value of liraglutide in patients with type 2 diabetes mellitus complicated with nonalcoholic fatty liver disease.Methods:150 patients with type 2 diabetes mellitus complicated with nonalcoholic fatty liver disease admitted to the First Affiliated Hospital of Xinxiang Medical College from August 2019 to August 2020 were randomly divided into two groups,75 cases in each group.The control group was treated with routine treatment,and the observation group was treated with liraglutide.The changes of blood glucose,blood lipid,liver fat deposition and adverse reactions were compared between the two groups.Results:Before treatment,there was no significant difference in the levels of fasting blood glucose,triglyceride and other indicators between the two groups(P>0.05);after treatment,the levels of fasting blood glucose,2 h postprandial blood glucose,glycosylated hemoglobin,triglyceride,total cholesterol and low density lipoprotein cholesterol in the observation group were(4.37±1.12)mmol/L,(6.57±1.02)mmol/L,(5.01±0.56)%,(1.72±0.59)mmol/L,(5.01±1.06)mmol/L,(2.33±0.54)mmol/L,were lower than that of the control group,the difference was statistically significant(P<0.05).Before treatment,there was no significant difference in fat controlled attenuation parameters and liver hardness index between the two groups(P>0.05);after treatment,the fat controlled attenuation parameters and liver hardness values of the observation group were(190.95±38.26)dB/m and(5.46±2.54)kPa were lower than that of the control group,the difference was statistically significant(P<0.05).The incidence of adverse reactions in the two groups was similar,the difference was not statistically significant(P>0.05).Conclusion:liraglutide has high application value in patients with type 2 diabetes mellitus complicated with nonalcoholic fatty liver disease.It can effectively improve blood lipid and blood glucose levels,reduce liver fat deposition,and is safe and reliable.